Skip directly to content

NEWS

Europe ASPIRE 2016 Awarded Proposals in Inflammation Research:

Helen L. Wright (Institute of Ageing and Chronic Diseases, University of Liverpool, United Kingdom)
The effect of JAK inhibition on neutrophil killing, NETosis and metabolism in rheumatoid arthritis

Marta Rizzi (University Medical Centre Freiburg, Germany)
Impact of Janus kinase inhibition on human early and late B cell development

Giovanni Almanzar (University Hospital Wuerzburg, Germany)
Varicella-zoster-virus-(VZV)-specific cellular immune response of in vitro tofacitinib-treated lymphocytes derived from patients with autoimmune arthritis

Sergei Nedospasov (Deutsches Rheuma-Forschungszentrum Berlin, Germany)
Combined blockade of TNF and JAK-STAT pathways in murine models of autoimmune arthritis

Thomas Karonitsch (Medical University of Vienna, Austria)
Epigenetic reprogramming of rheumatoid fibroblast-like synoviocytes (RA-FLS) with JAKinibs

Elisabetta Botti (University of Rome “Tor Vergata”, Italy)
JAK-STAT signaling inhibition on autoantigen driven psoriatic inflammation

Friederike Berberich-Siebelt (University of Würzburg, Germany)
A novel Jakinib in the dichotomy of mucosal healing and inflammation-associated cancer resolution

Prof. dr. Maikel P. Peppelenbosch (Erasmus MC, Rotterdam)
The effect of the microbiome on JAK/STAT/SOCS signaling in the intestinal epithelial compartment of IBD patients

Konrad Aden (Christian-Albrechts-Universitat zu Kiel, Germany)
Dissecting the role of tofacitinib on epithelial stem cell function and intestinal repair

Europe ASPIRE 2015 Awarded Proposals in Inflammation Research:

Thomas Huizinga (Leiden University Medical Center, Netherlands)
Exploring the disease modifying effects of tofacitinib: Does tofacitinib affect intracellular signalling pathways involved in the regulation of autoantibody production in rheumatoid arthritis?

Cristina Albanesi (IstitutoDermopaticodell’Immacolata IDI-IRCCS, Italy)
Immunomodulatory effects of tofacitinib on psoriatic keratinocytes and on its capability to mimic SOCS inhibitory circuits

Rik Lories (KU Leuven, Belgium)
Control of cartilage damage by inhibition of JAK-STAT signalling: Identifying signalling networks

JannekeNicolineSamsom (Erasmus University Medical Center, Netherlands)
Tofacitinib to treat inflammatory bowel disease which is driven by defective antigen presenting cell function

Axel J. Hueber (Friedrich-Alexander University Erlangen-Nuernberg, Germany)
Dissecting JAK-STAT dependent bone-turnover in autoimmune arthritis

Europe ASPIRE 2014 Awarded Proposals in Inflammation Research:

Dirk Foell (University of Muenster, Germany)
Regulatory monocytes induces by blocking JAKs in inflammatory diseases

Antonio Costanzo (Sapienza University of Rome, Italy)
Effects of JAK3 inhibition on transcriptional landscapes in psoriasis

Ursula Fearon (St Vincent’s University Hospital, Ireland)
Tofacitinib inhibits synovial invasiveness, bioenergetics and bone resorption in RA

EnikoSonkolty (Karolinska University Hospital, Sweden)
Investigation of the role of microRNAs in the mechanism of action of JAK/STAT inhibitors in psoriasis

Markus F. Neurath (University of Erlangen-Nuernberg, Germany)
Effects of tofacitinib on intestinal epithelial cells and mucosal healing in inflammatory bowel diseases

Europe ASPIRE 2013 Awarded Proposals in Inflammation Research:

Marie-Christophe Boissier (University of Paris 13,France)
Translational study of tofacitinib-mediated JAK inhibition on neutrophil activation and apoptosis in TNF-alpha-transgenic mice and rheumatoid arthritis

JoãoEurico Fonseca (Instituto de Medicina Molecular, Portugal)
Inhibition of bone and cartilage degradation in rat induced arthritis treated with tofacitinib

Thomas Harrer (University Hospital Erlangen, Germany)
Pharmacodynamic risk assessment of immunodeficiency during treatment with JAK3-inhibitors

Gabriel Herrero-Beaumont (Joint and Bone Research Unit. IIS-Fundación Jiménez Diaz, Spain)
Effect of tofacitinib in the systemic and tisularinflammatory profile in an experimental model of rheumatoid cachexia

Jens Thiel (University Hospital Freiburg, Germany)
Dissecting JAK-STAT dependent bone-turnover in autoimmune arthritis

Date of preparation: May 2017
PP-XEL-EUR- 0520